Aquestive Therapeutics to Participate in Key Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a forward-thinking pharmaceutical company, is gearing up to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference taking place soon. This prestigious event is set to shine a spotlight on their latest innovations aimed at improving patients' lives.
Engaging Conversations on New Product Candidate
The management team from Aquestive is excited to hold a fireside chat with David Amsellem, a Senior Research Analyst at Piper Sandler. This engaging conversation is scheduled for December 4 and promises to delve into the company’s promising product candidate, Anaphylm™ (dibutepinephrine) sublingual film, discussing its regulatory progress and commercial readiness.
Investor Meetings to Discuss Future Developments
In addition to the fireside chat, the Aquestive team will host crucial investor meetings throughout the day. These meetings will focus on upcoming strategies and the significant steps the company is taking in the pharmaceutical realm, highlighting their commitment to innovation.
Access to the Webcast for Investors
For those unable to attend the conference in person, a webcast of the fireside chat will be accessible via the Investors section of the company’s website. Additionally, a replay of the discussion will be available for a month following the event to ensure that all interested parties can catch up on the insights shared.
About Aquestive Therapeutics
Aquestive Therapeutics is a trailblazer in the pharmaceutical industry, dedicated to developing innovative medicines that make a real difference in patients' lives. Their focus is on creating both orally administered and topical gel products designed to effectively deliver complex molecules. The company is at the forefront of providing novel alternatives to traditional treatments, ensuring that patient care is as effective and convenient as possible.
Impressive Portfolio of Marketed Products
Aquestive has successfully commercialized four products through its licensees, showcasing its ability to bring complex therapies to both the U.S. and global markets. As the exclusive manufacturer of these products, the company stands out for its proven drug development capabilities and commitment to collaboration with other pharmaceutical entities to introduce new molecules into the marketplace.
Commitment to Innovative Solutions
Currently, Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis. Additionally, they are working on an early-stage epinephrine prodrug topical gel product intended for a variety of dermatological conditions, underscoring their commitment to innovative solutions in medicine.
Connect With Us
For more information about their advancements and innovative pipeline, visit Aquestive.com. Following them on LinkedIn can provide insights into their ongoing journey in the pharmaceutical industry.
Frequently Asked Questions
What is Aquestive Therapeutics known for?
Aquestive Therapeutics is recognized for its innovative pharmaceutical products aimed at improving patient health, particularly through novel drug delivery technologies.
When will the fireside chat occur?
The fireside chat featuring the company’s management and Piper Sandler’s David Amsellem is scheduled for December 4, 2025, at 10:00 a.m. ET.
How can I access the webcast?
The webcast of the fireside chat will be available on the Investors page of Aquestive’s website, with a replay accessible for 30 days following the event.
Which product candidate will be discussed?
The discussion will mainly focus on Anaphylm™ (dibutepinephrine) sublingual film, highlighting its regulatory progress and readiness for market.
What types of products does Aquestive develop?
Aquestive develops orally administered and topical gel products, emphasizing the delivery of complex molecules and providing alternative therapeutic solutions.